• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺部感染：治疗障碍与药物研发进展

Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development.

作者信息

Charrier Elise Si Ahmed, Dassonville-Klimpt Alexandra, Andréjak Claire, Sonnet Pascal

机构信息

Agents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.

Service de Pneumologie, CHU Amiens-Picardie, 80000 Amiens, France.

出版信息

Pharmaceuticals (Basel). 2025 Jun 13;18(6):891. doi: 10.3390/ph18060891.

DOI:10.3390/ph18060891
PMID:40573286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12195860/
Abstract

Worldwide, several million people are infected with mycobacteria such as () or non-tuberculous mycobacteria (NTM). In 2023, 10.8 million cases and 1.25 million deaths due to were recorded. In Europe and North America, the emergence of NTM is tending to outstrip that of . Among pulmonary NTM, (MAC) is the most common, accounting for 80% of NTM infections. First-line treatment requires the combination of at least three antibiotics over a long period and with different mechanisms of action to limit cross-resistance. The challenge is to discover more effective new anti-MAC molecules to reduce the duration of treatment and to overcome resistant strains. The aim of this review is to present an overview of the challenges posed by MAC infection such as side effects, reinfections and resistance mechanisms. The latest therapeutic options such as the optimized combination therapy, drug repurposing and the development of new formulations, as well as new anti-MAC compounds currently in (pre)clinical trials will also be discussed.

摘要

在全球范围内，数百万人感染了诸如（）或非结核分枝杆菌（NTM）等分枝杆菌。2023年，记录了1080万例结核病病例和125万例结核病死亡病例。在欧洲和北美，非结核分枝杆菌的出现趋势超过了结核病。在肺部非结核分枝杆菌中，鸟分枝杆菌复合群（MAC）最为常见，占非结核分枝杆菌感染的80%。一线治疗需要长期联合使用至少三种具有不同作用机制的抗生素，以限制交叉耐药性。挑战在于发现更有效的新型抗MAC分子，以缩短治疗时间并克服耐药菌株。本综述的目的是概述MAC感染带来的挑战，如副作用、再感染和耐药机制。还将讨论最新的治疗选择，如优化联合治疗、药物重新利用和新制剂的开发，以及目前处于（前）临床试验阶段的新型抗MAC化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/4565752f3be7/pharmaceuticals-18-00891-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/47c9a327b56e/pharmaceuticals-18-00891-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/e55fd3a7357a/pharmaceuticals-18-00891-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/d50b159f1df3/pharmaceuticals-18-00891-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/986a8babb355/pharmaceuticals-18-00891-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/32e82db9ce71/pharmaceuticals-18-00891-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/3c8dc617d6cf/pharmaceuticals-18-00891-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/466446a66413/pharmaceuticals-18-00891-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/534ad499b6af/pharmaceuticals-18-00891-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/5f83e46653ec/pharmaceuticals-18-00891-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/b53643570669/pharmaceuticals-18-00891-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/92f2dde1d465/pharmaceuticals-18-00891-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/304174a94cec/pharmaceuticals-18-00891-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/d5bc328c26ae/pharmaceuticals-18-00891-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/7142fc625f82/pharmaceuticals-18-00891-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/bb3e1927a6b6/pharmaceuticals-18-00891-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/726c5c5942a6/pharmaceuticals-18-00891-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/b6dd59d74f2e/pharmaceuticals-18-00891-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/acae3bd36ec9/pharmaceuticals-18-00891-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/11f49a9b41e7/pharmaceuticals-18-00891-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/776d333bea9c/pharmaceuticals-18-00891-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/4565752f3be7/pharmaceuticals-18-00891-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/47c9a327b56e/pharmaceuticals-18-00891-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/e55fd3a7357a/pharmaceuticals-18-00891-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/d50b159f1df3/pharmaceuticals-18-00891-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/986a8babb355/pharmaceuticals-18-00891-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/32e82db9ce71/pharmaceuticals-18-00891-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/3c8dc617d6cf/pharmaceuticals-18-00891-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/466446a66413/pharmaceuticals-18-00891-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/534ad499b6af/pharmaceuticals-18-00891-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/5f83e46653ec/pharmaceuticals-18-00891-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/b53643570669/pharmaceuticals-18-00891-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/92f2dde1d465/pharmaceuticals-18-00891-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/304174a94cec/pharmaceuticals-18-00891-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/d5bc328c26ae/pharmaceuticals-18-00891-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/7142fc625f82/pharmaceuticals-18-00891-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/bb3e1927a6b6/pharmaceuticals-18-00891-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/726c5c5942a6/pharmaceuticals-18-00891-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/b6dd59d74f2e/pharmaceuticals-18-00891-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/acae3bd36ec9/pharmaceuticals-18-00891-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/11f49a9b41e7/pharmaceuticals-18-00891-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/776d333bea9c/pharmaceuticals-18-00891-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68e6/12195860/4565752f3be7/pharmaceuticals-18-00891-g021.jpg

相似文献

1
Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development.肺部感染：治疗障碍与药物研发进展
Pharmaceuticals (Basel). 2025 Jun 13;18(6):891. doi: 10.3390/ph18060891.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
4
Population-based interventions for reducing sexually transmitted infections, including HIV infection.基于人群的减少性传播感染（包括艾滋病毒感染）的干预措施。
Cochrane Database Syst Rev. 2004(2):CD001220. doi: 10.1002/14651858.CD001220.pub2.
5
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.快速分子检测结核分枝杆菌和结核分枝杆菌耐药性：受检者和提供者观点的定性证据综合评价。
Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2.
6
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.戒烟药物和电子烟：系统评价、网络荟萃分析和成本效益分析。
Health Technol Assess. 2021 Oct;25(59):1-224. doi: 10.3310/hta25590.
7
Population-based interventions for reducing sexually transmitted infections, including HIV infection.基于人群的减少性传播感染（包括艾滋病毒感染）的干预措施。
Cochrane Database Syst Rev. 2001(2):CD001220. doi: 10.1002/14651858.CD001220.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.用于肺外结核病和利福平耐药性的Xpert MTB/RIF检测
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
10
The activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; and complex: A systematic review.碳青霉烯类单独及与β-内酰胺酶抑制剂联合应用对难治疗分枝杆菌及复合体的活性：一项系统评价
Int J Mycobacteriol. 2023 Jul-Sep;12(3):211-225. doi: 10.4103/ijmy.ijmy_131_23.

本文引用的文献

1
Phenothiazines boost host control of Mycobacterium avium infection in primary human macrophages.吩噻嗪增强原代人巨噬细胞对鸟分枝杆菌感染的宿主控制。
Biomed Pharmacother. 2025 Apr;185:117941. doi: 10.1016/j.biopha.2025.117941. Epub 2025 Feb 27.
2
Mefloquine reduces the bacterial membrane fluidity of and distorts the bacterial membrane when combined with polymyxin B.甲氟喹与多粘菌素B联合使用时，可降低细菌膜流动性并使细菌膜变形。
mBio. 2025 Apr 9;16(4):e0401624. doi: 10.1128/mbio.04016-24. Epub 2025 Feb 25.
3
Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment.
作为联合抑菌治疗的抗生素佐剂的甲氟喹研究进展。
Front Cell Infect Microbiol. 2024 Nov 28;14:1470891. doi: 10.3389/fcimb.2024.1470891. eCollection 2024.
4
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.健康志愿者口服 SPR720 后 SPK719 的肺部药代动力学。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0110324. doi: 10.1128/aac.01103-24. Epub 2024 Oct 1.
5
Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection.甲氟喹及其对映异构体在感染鸟分枝杆菌的小鼠模型中的疗效。
PLoS One. 2024 Sep 30;19(9):e0311167. doi: 10.1371/journal.pone.0311167. eCollection 2024.
6
Sub-MIC levels of bedaquiline and clofazimine can select mutants with increased MIC.贝达喹啉和氯法齐明的亚最低抑菌浓度可选择 MIC 值升高的突变体。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0127523. doi: 10.1128/aac.01275-23. Epub 2024 Mar 12.
7
Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.SPR720 在非结核分枝杆菌肺部感染的小鼠模型中的疗效。
J Antimicrob Chemother. 2024 Apr 2;79(4):875-882. doi: 10.1093/jac/dkae046.
8
Why do we use 100 mg of clofazimine in TB and NTM treatment?为什么我们在结核病和非结核分枝杆菌治疗中使用 100 毫克氯法齐明？
J Antimicrob Chemother. 2024 Apr 2;79(4):697-702. doi: 10.1093/jac/dkae041.
9
Mavintramycin A is a promising antibiotic for treating complex infectious disease.马文他霉素 A 是一种很有前途的抗生素，可用于治疗复杂的传染病。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0091723. doi: 10.1128/aac.00917-23. Epub 2024 Feb 9.
10
Sudapyridine (WX-081) antibacterial activity against , , and and .舒巴吡啶（WX-081）对 、 、 和 的抗菌活性。
mSphere. 2024 Feb 28;9(2):e0051823. doi: 10.1128/msphere.00518-23. Epub 2024 Jan 19.